| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Heparin is one of the most important anticoagulant drugs. Heparin also has a variety of anti-inflammatory functions, and is clinically used as an anti-inflammatory drug. However, little is known about the regulatory effects of heparin on the upper airway inflammation.
We have examined the in vivo and in vitro effects of heparin on mucus hypersecretion in airway epithelial cells. Intranasal instillation with heparin significantly inhibited lipopolysaccharides (LPS)-induced and antigen-induced mucus hypersecretion in rat nasal epithelium. Mucosal infiltration of neutrophils and eosinophils were also significantly attenuated. The in vitro effects of heparin on secretion of mucin and cytokines were examined using cultured airway epithelial cells (NCI-H292). Heparin significantly inhibited TNF-α-induced secretion of mucin (MUC5AC) and IL-8. These results indicated that local administration with heparin may provide a new therapeutic strategy for upper airway inflammation.
|
